Cell Lysis and Fractionation Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cell lysis and fractionation market size has grown strongly in recent years. It will grow from $3.42 billion in 2024 to $3.72 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing investments in life science research, growing focus on personalized medicine, high prevalence of diseases, technological advancements in cell lysis and fractionation methods, rising demand for biopharmaceuticals and biotechnology products.

The cell lysis and fractionation market size is expected to see strong growth in the next few years. It will grow to $4.89 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growing focus on personalized medicine, increasing government funding for research, high demand for effective cell lysis and fractionation methods, technological advancements in the field of genomics and proteomics, rising prevalence of chronic and infectious diseases. Major trends in the forecast period include continued growth in the adoption of personalized medicine approaches, increasing integration of automation and robotics in lysis and fractionation processes, expansion of applications in clinical diagnostics and drug development, advancements in microfluidics and lab-on-a-chip technologies for cell analysis, growing emphasis on point-of-care and decentralized testing solutions.

A growing focus on personalized medicine is expected to propel the growth of the cell lysis and fractionation markets going forward. Personalized medicine is an emerging practice of medicine that uses an individual's genetic profile for the diagnosis and treatment of disease. It involves tailoring medical decisions and treatments to the individual characteristics of each patient, particularly focusing on their genetic makeup. Cell lysis and fractionation play a crucial part in precision medicine by making it possible to separate and analyze particular subcellular elements from patient samples, including proteins, organelles, and nucleic acids. This makes it possible for scientists and medical professionals to investigate the molecular processes that underlie illness and create customized treatments depending on the unique molecular traits of each patient. For instance, in October 2022, according to the Personalized Medicine Coalition (PMC), a US-based organization that promotes understanding and adoption of personalized medicine, more than 75,000 genetic testing products and 300 personalized medicines will be on the market for people with multiple types of cancer, genetic rare diseases, and a range of chronic and infectious diseases. Therefore, the growing focus on personalized medicine is driving the growth of the cell lysis and fractionation markets.

Major companies operating in the cell lysis and fractionation market are focused on introducing advanced solutions, such as CGT (cell and gene therapy) viral vector lysis kits, to gain a competitive edge in the market. These lysis kits offer a simplified AAV (Adeno-associated virus) lysis methodology that will improve SOPs (Standard Operating Procedures), quality control, and safety while standardizing bioprocessing workflows. For instance, in July 2023, QIAGEN, a Germany-based provider of sample and assay technologies, launched the new CGT Viral Vector Lysis Kit, which makes it possible to quantify virus titers for several serotypes with an exact and uniform procedure starting with cell lysates. The new CGT viral vector lysis kit complements QIAGEN's rapidly expanding digital PCR portfolio for the biopharma industry, which already includes three QIAcuity Residual DNA Quantification Kits to check for host cell DNA carryover and ten QIAcuity Cell and Gene Therapy (CGT) dPCR Assays for use in adeno-associated virus (AAV) titer quantification.

In December 2022, MilliporeSigma, a US-based pharmaceutical company, acquired Erbi Biosystems Inc. for an undisclosed amount. With this acquisition, MilliporeSigma aims to strengthen its portfolio and expertise in the field of bioreactors and cell culture technologies. Erbi Biosystems is the developer of the 2 ml micro-bioreactor platform technology known as Breez, which is a micro-scale, fully automated, functionally closed system. Erbi Biosystems Inc. is a US-based biotechnology company that offers microfluidic solutions to enable efficient and controlled cell lysis and fractionation.

Major companies operating in the cell lysis and fractionation market are Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Lonza Group AG, Illumina Inc., Beckman Coulter Inc., PerkinElmer Inc., IDEX Corporation, Bio-Rad Laboratories Inc., QIAGEN NV, Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, Promega Corporation, Takara Bio Inc., Abcam plc, Cell Signaling Technology Inc., BioVision Inc., Diagenode LLC, Claremont BioSolutions LLC, Norgen Biotek Corp., Qsonica LLC, Labfreez Instruments Group Co. Ltd.

North America was the largest region in the cell lysis and fractionation market in 2024. The regions covered in the cell lysis and fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell lysis and fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell lysis and fractionation market consists of revenues earned by entities by providing cellular contents extraction, cytoplasmic separation, and cell disruption. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell lysis and fractionation market also includes sales of cell lysis instruments, cell lysis reagents, and consumables. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Cell lysis is the process of breaking open a cell, which allows the release of its contents, while cell fractionation is a multi-step laboratory procedure used to divide a cell's organelles into various layers or fractions or sections.

The main types of cell lysis and fractionation are mammalian cells and microbial cells. Mammalian cells are eukaryotic cells that are derived from mammals and are used in cell culture and biomanufacturing of therapeutic proteins and viral vaccines. These are used for various applications, such as nucleic acid purification and isolation and protein purification and isolation, and are used by several end users, including research laboratories and institutes, biopharmaceutical, and biotechnology companies.

The main types of cell lysis and fractionation are mammalian cells and microbial cells. Mammalian cells are eukaryotic cells that are derived from mammals and are used in cell culture and biomanufacturing of therapeutic proteins and viral vaccines. These are used for various applications, such as nucleic acid purification and isolation and protein purification and isolation, and are used by several end users, including research laboratories and institutes, biopharmaceutical, and biotechnology companies.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.